Across TCGA pan-cancer cohorts, PTAR1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of PTAR1’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where PTAR1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types PTAR1 is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

HNSC, LSCC, and CCRCC are the cancer types where PTAR1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in PTAR1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	III,IV	+0.180	<.001	11	view →
LSCC	All	III,IV	−0.179	<.001	7	view →
CCRCC	All	All	+0.113	<.001	6	view →
PDAC	All	All	−0.230	.029	1	view →
LUAD	Male	II,III,IV	−0.106	.038	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PTAR1 RNA expression & survival · all PTAR1 data types